Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.
Want the full AI research report for SH PHARMA?
This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.
New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.
10-Year FinancialsFY2016–2025
Financial statements are reported in CNY, while share price and market cap are quoted in HKD.
Key Multi-Year Facts
- Revenue moved from CN¥120.8B in FY2016 to CN¥283.6B in FY2025 (9-year CAGR +9.9%).
- Profitable in every fiscal year across 2016–2025.
- Operating cash flow was below half of net income in FY2016, FY2017, FY2018.
Latest 5 Fiscal Years
| Fiscal Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue (CNY B) | 216 | 232 | 260 | 275 | 284 |
| YoY | 12.5% | 7.5% | 12.2% | 5.7% | 3.0% |
| Net Income (CNY B) | 5.09 | 5.62 | 3.77 | 4.55 | 5.72 |
| YoY | 13.3% | 10.3% | -32.9% | 20.8% | 25.7% |
| Operating Cash Flow (CNY B) | 5.06 | 4.74 | 5.23 | 5.83 | 6.15 |
| ROE | 10.8% | 9.6% | 5.6% | 6.5% | 7.8% |
| Gross Margin | 13.2% | 13.1% | 12.0% | 11.1% | 10.7% |
| Net Margin | 2.4% | 2.4% | 1.4% | 1.7% | 2.0% |
| Debt-to-Assets | 63.9% | 60.6% | 62.1% | 62.1% | 61.5% |
Show all 10 fiscal years
| Fiscal Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (CNY B) | 121 | 131 | 159 | 187 | 192 | 216 | 232 | 260 | 275 | 284 |
| YoY | — | 8.3% | 21.6% | 17.3% | 2.9% | 12.5% | 7.5% | 12.2% | 5.7% | 3.0% |
| Net Income (CNY B) | 3.20 | 3.52 | 3.88 | 4.08 | 4.50 | 5.09 | 5.62 | 3.77 | 4.55 | 5.72 |
| YoY | — | 10.1% | 10.2% | 5.2% | 10.2% | 13.3% | 10.3% | -32.9% | 20.8% | 25.7% |
| Operating Cash Flow (CNY B) | 1.22 | 1.64 | 1.60 | 6.02 | 6.84 | 5.06 | 4.74 | 5.23 | 5.83 | 6.15 |
| ROE | 10.1% | 10.7% | 10.6% | 10.1% | 10.3% | 10.8% | 9.6% | 5.6% | 6.5% | 7.8% |
| Gross Margin | 11.5% | 12.4% | 13.6% | 14.4% | 13.9% | 13.2% | 13.1% | 12.0% | 11.1% | 10.7% |
| Net Margin | 2.6% | 2.7% | 2.4% | 2.2% | 2.3% | 2.4% | 2.4% | 1.4% | 1.7% | 2.0% |
| Debt-to-Assets | — | 57.9% | 63.4% | 64.0% | 63.3% | 63.9% | 60.6% | 62.1% | 62.1% | 61.5% |
Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings
Risk ChecklistAs of 2026-11-05
Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).
Items Flagged for Review
- Watch
-
Watch
Short-Term Debt CoverageSolvency
Cash CN¥32.40B, short-term debt CN¥44.74B (0.72x)
Q3 (2026-09-30) · What is this?
An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.
Dividends
Trailing 12-month dividend: HK$0.521 per share, or 4.66% yield at closing price; last full fiscal year: HK$0.537 (payout ratio 32.9%).
Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.
More data: All research reports · Sector leaders · Market hours & holidays.
Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.